This article has Open Peer Review reports available.
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence
© Papp et al; licensee BioMed Central Ltd. 2006
Received: 11 May 2006
Accepted: 26 October 2006
Published: 26 October 2006
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|11 May 2006||Submitted||Original manuscript|
|23 Jun 2006||Reviewed||Reviewer Report - Dan Pearce|
|7 Jul 2006||Reviewed||Reviewer Report - Jennifer Cather|
|15 Aug 2006||Author responded||Author comments - Kim Papp|
|Resubmission - Version 2|
|15 Aug 2006||Submitted||Manuscript version 2|
|25 Aug 2006||Author responded||Author comments - Kim Papp|
|Resubmission - Version 3|
|25 Aug 2006||Submitted||Manuscript version 3|
|13 Sep 2006||Reviewed||Reviewer Report - Jennifer Cather|
|2 Oct 2006||Reviewed||Reviewer Report - Dan Pearce|
|Resubmission - Version 4|
|Submitted||Manuscript version 4|
|26 Oct 2006||Editorially accepted|
|26 Oct 2006||Article published||10.1186/1471-5945-6-9|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.